Extension of exclusive agreement with bene pharmaChem
Filed with ASX · · 2 pages · English
Paradigm Biopharmaceuticals Ltd. on 6ix
Earlier from Paradigm Biopharmaceuticals
- EMA provides key path toward phase 3 trials and registration
- Paradigm Presentation to Emerging Leaders Conference
- Appendix 4E and 2020 Annual Report
- MPS receives critical approvals and feedback from agencies
- Quarterly Activities Report
Later from Paradigm Biopharmaceuticals
- Zilosul reduces pain in patients with knee OA
- First patient dosed in MPS-I Phase 2 clinical trial
- Paradigm Provides Phase 3 Clinical Trial Update
- Paradigm receives postive feedback from FDA type c meeting
- R&D Investor Presentation
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals